Remternetug
mAbexperimental
Clinical trial activity
6 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
3
Phase 4
0
Earliest trial started Nov 5, 2018 (NCT03720548)
Timeline
Indications
Mechanism of action
- Beta amyloid A4 proteinINHIBITOR
APP inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095484 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07056309 | Phase 1 | Jun 24, 2025 | Eli Lilly |
| NCT06647498 | Phase 2/Phase 3 (Phase 3) | Nov 30, 2024 | Alzheimer's Association, Eli Lilly, National Institute on Aging (NIA), Washington University in St. Louis |
| NCT06653153 | Phase 3 | Oct 31, 2024 | Eli Lilly |
| NCT05463731 | Phase 3 | Aug 1, 2022 | Eli Lilly |
| NCT04451408 | Phase 1 | Jul 7, 2020 | Eli Lilly |
| NCT03720548 | Phase 1 | Nov 5, 2018 | Eli Lilly |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 6 | 5 | 2 | 2018 |
| Alzheimer's Association | Academic/Hospital | 1 | 0 | 1 | 2024 |
| National Institute on Aging (NIA) | Government | 1 | 0 | 1 | 2024 |
| Washington University in St. Louis | Academic/Hospital | 1 | 1 | 1 | 2024 |
4 organizations
Page 1 / 1